Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
NASDAQ:MDWD
Holding MDWD?
Track your performance easily
MDWD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.41 - $24.00
Previous Close$16.48
Volume76.09K
Average Volume (3M)44.48K
Market Cap
$177.76M
Enterprise Value$142.40M
Total Cash (Recent Filing)$41.71M
Total Debt (Recent Filing)$6.35M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Nov 26, 2024EPS Estimate
-$0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.16
Shares Outstanding10,790,000
10 Day Avg. Volume52,962
30 Day Avg. Volume44,479
Standard Deviation0.17
R-Squared0.06
Alpha0.00267
Financial Highlights & Ratios
Price to Book (P/B)5.73
Price to Sales (P/S)9.12
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.60
Enterprise Value/Gross Profit39.80
Enterprise Value/Ebitda-21.89
Forecast
1Y Price Target
$26.50Price Target Upside52.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Mediwound News
PremiumCompany Announcements
MediWound Advances with FDA Approval and New Funding
PremiumCompany Announcements
MediWound to Discuss New Share Incentive Plan
PremiumCompany Announcements
MediWound’s NexoBrid Gains FDA Pediatric Approval
Bulls Say, Bears Say
Bulls Say
Market ExpansionNexoBrid is rolling out in two new markets outside the US: Japan, through Kaken Pharmaceutical, and India, through Bharat Serums and Vaccines.
Product DevelopmentEscharEx is being developed for enzymatic debridement of chronic wounds in the outpatient setting, representing a potential ~$2B market opportunity.
Strategic PartnershipsCollaboration with Mölnlycke Health Care and Solventum is expected to strengthen MediWound’s relationships with strategic partners.
Bears Say
Business RisksRisks to the company include clinical, regulatory, commercial, collaboration, financial, and intellectual property challenges.
Financial PerformanceThe operating loss was $4.5M, while the net loss was $6.3M, or $0.68 per share.
Regulatory ChallengesAwaiting PDUFA Date for Clarity on Path Forward for MDMA-AT – Maintain Hold.
---
Ownership Overview
―
Insiders
1.79% Mutual Funds
27.18% Other Institutional Investors
66.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $8.41 and its highest was $24.00 in the past 12 months.
What is Mediwound’s market cap?
Currently, no data Available
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is Nov 26, 2024 which is yesterday.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on Aug 14, 2024. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.42 by -$0.26.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -$0.48.
How many shares outstanding does Mediwound have?
Mediwound has 10,786,423 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.42. Following the earnings report the stock price went down -4.064%.
Which hedge fund is a major shareholder of Mediwound?
Among the largest hedge funds holding Mediwound’s share is ARK Investment Management LLC. It holds Mediwound’s shares valued at 2M.
---
Mediwound Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.50 (52.91% Upside)
$26.50 (52.91% Upside)
Blogger Sentiment
Bullish
MDWD Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 100.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.42%
12-Months-Change
Fundamentals
Return on Equity
-75.66%
Trailing 12-Months
Asset Growth
-10.98%
Trailing 12-Months
Company Description
Mediwound
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.
---
MDWD Earnings Call
Q2 2024
0:00 / 0:00
---
MDWD Stock 12 Month Forecast
Average Price Target
$26.50
▲(52.91% Upside)
Technical Analysis
Best Analysts Covering MDWD
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+41.44%
reiterated a buy rating 3 months ago
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +41.44% per trade.
---